Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 5/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | TDO2 | P48775 | 3/20 | 0.43 |
| ▸ | IDO2 | Q6ZQW0 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23065101 | 0.90 | MEN1 (0.48) | ALDH1A1MEN1KMT2AHSD17B10ACP1 | |
| SCHEMBL24089906 | 0.89 | ACP1 (0.50) | ALDH1A1MEN1KMT2AHSD17B10ACP1 | |
| SCHEMBL24090101 | 0.89 | ACP1 (0.51) | ALDH1A1ACP1AVPR1BFAAHSMN1; SMN2 | |
| SCHEMBL29623188 | 0.88 | MEN1 (0.52) | ALDH1A1MEN1KMT2AHSD17B10ACP1 | |
| SCHEMBL23065098 | 0.88 | MEN1 (0.52) | ALDH1A1MEN1KMT2AHSD17B10ACP1 | |
| SCHEMBL29623301 | 0.86 | TOP2A (0.48) | ALDH1A1TDO2IDO2HTR7 | |
| SCHEMBL24089966 | 0.86 | TOP2A (0.48) | ALDH1A1TDO2IDO2HTR7 | |
| SCHEMBL24090098 | 0.83 | TDO2 (0.49) | ALDH1A1ACP1IDO1TDO2IDO2 | |
| SCHEMBL23045334 | 0.82 | TDO2 (0.50) | IDO1TDO2IDO2HTR7SMN1; SMN2 | |
| SCHEMBL29623155 | 0.82 | TDO2 (0.50) | IDO1TDO2IDO2HTR7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | claimed |
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | ALDH1A1 645/4885MEN1 1124/4885KMT2A 1257/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | ALDH1A1 739/4885MEN1 1282/4885KMT2A 967/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | ALDH1A1 739/4885MEN1 1282/4885KMT2A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.